Neuraxpharm Group has acquired oral dosage forms Provigil (modafinil) and Nuvigil (armodafinil).
The two stimulant therapeutics are approved for use in adult patients with narcolepsy, and are widely prescribed to combat excessive daytime sleepiness (EDS).
Through this deal, which was closed in December 2024, Neuraxpharm owns the exclusive rights to these drugs in most markets outside of the US, Korea, Japan and Thailand.
Currently, Provigil is most successful in the European region, whereas Nuvigil has sold best in Australia and Mexico.
Both drugs are suitable for patients with and without cataplexy.
Neuraxpharm bolsters its CNS therapeutic offering
According to Neuraxpharm, this acquisition aligns with its strategy to develop a strong footing in CNS diseases, while also bringing vital therapeutics to more patients in need worldwide.
Through buying Nugivil, the company will also expand its presence into Australia, where it is already planning to launch its first-in-class drug Briumvi (ublituximab), which will be used to treat patients with multiple sclerosis.
CEO of Neuraxpharm, Dr Jörg-Thomas Dierks, commented: “Today’s acquisition is an example of how Neuraxpharm can harness its neurology-focused approach, broad international platform and entrepreneurial capabilities to expand strong CNS brands."
"These two leading narcolepsy treatments will be added to our broad and growing CNS portfolio. We will leverage our specialisation and reach to grow these products in existing and new markets, thereby bringing market-leading treatments to more CNS patients with unmet needs around the world.”